Observational studyBMC pulmonary medicine2026
Clofazimine use for nontuberculous mycobacterial infections: 10-year experience in Belgium.
Observational study in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClofazimine is increasingly recommended for nontuberculous mycobacterial (NTM) infections, despite limited evidence. In Belgium, until July 2025 access to clofazimine - outside of procurement by the national tuberculosis program - was restricted and associated with financial and administrative hurdles, creating barriers for patients.
methodsThis retrospective, multicentre study documents clofazimine use from January 2015 to December 2024 through pharmacy and medical record review at Belgium's two largest tertiary care hospitals. Collected data included indications, treatment duration, adverse events and logistic aspects related to access. Data was summarized using descriptive statistics.
resultsAmong 102 clofazimine-containing treatment courses for NTM disease (61 in UZ Leuven; 41 in UZ Gent), the median patient age was 62 years; 52% were female, 56% had bronchiectasis, 28% COPD and 12% cystic fibrosis. Clofazimine was mainly used for NTM-pulmonary disease (NTM-PD) (n = 82, 87.2%), with main indications being M. abscessus complex-PD (MAB-PD; 28%), advanced or refractory M. avium complex-PD (MAC-PD; 17% and 12.2% respectively) or intolerance to another key drug (26.8%). Clofazimine was part of at least a triple-drug regimen, with 100 mg daily used in 91% of regimens for a median duration of 270 days (IQR 109-527 days). Common adverse events included ichthyosis/skin hyperpigmentation (38.3%) and gastrointestinal complaints (52.1%). Although none were severe, 20% of patients discontinued treatment prematurely. Financial reimbursement requests were submitted for 68.2% of NTM-PD treatments.
conclusionOur study observed that clofazimine is prescribed largely in accordance with current guideline recommendations. Given its acceptable tolerability and the recent introduction of national health insurance coverage, clofazimine use is likely to increase in Belgium, with the potential to improve patient outcomes.
trial registrationThis study did not involve a health care intervention and did not meet criteria for clinical trial registration. It was conducted as a retrospective, multicentre study at UZ Leuven and UZ Gent. Ethical approval was obtained from the Ethics Committee of UZ/KU Leuven (MP034837, S70431) and the Ethics Committee of UZ Gent (S61188, S62926). CLINICAL TRIAL NUMBER: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.